Literature DB >> 28105500

[Discontinuation of benzodiazepines in old age : When and if so, how?]

Dirk K Wolter1.   

Abstract

Although viewed critically in geriatrics, benzodiazepine use is still common among old people. Before reducing the dosage the following questions must be considered: 1. Are there indications for benzodiazepine treatment and will discontinuation cause relevant rebound symptoms of the initial disorder treated? 2. To what extent do the patient and other key persons consider discontinuation to be reasonable and will they support discontinuation? 3. Is the target complete withdrawal, a dose reduction or shift to another benzodiazepine drug which is more suitable in old age for pharmacokinetic reasons? This article provides assistance in answering these questions and some guidelines for the practical management of discontinuation. It is mandatory 1) to periodically address the problem of long-term benzodiazepine use when counseling the patient and key persons and 2) to be aware that several intermediate steps exist between continuation and complete discontinuation, which may be considered successful treatment.

Entities:  

Keywords:  Anxiety disorders; Discontinuation program; Intoxication; Withdrawal; Z-drugs

Mesh:

Substances:

Year:  2017        PMID: 28105500     DOI: 10.1007/s00391-016-1171-5

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  31 in total

1.  Benzodiazepine substitution for dependent patients—going with the flow.

Authors:  Peter Tyrer
Journal:  Addiction       Date:  2010-11       Impact factor: 6.526

2.  Social-cognitive predictors of intended and actual benzodiazepine cessation among chronic benzodiazepine users.

Authors:  Geeske B Ten Wolde; Arie Dijkstra; Pepijn Van Empelen; Arie Knuistingh Neven; Frans G Zitman
Journal:  Addict Behav       Date:  2008-02-20       Impact factor: 3.913

Review 3.  Risk versus risk: a review of benzodiazepine reduction in older adults.

Authors:  Allison M Paquin; Kristin Zimmerman; James L Rudolph
Journal:  Expert Opin Drug Saf       Date:  2014-06-06       Impact factor: 4.250

Review 4.  The problems of long-term treatment with benzodiazepines and related substances.

Authors:  Katrin Janhsen; Patrik Roser; Knut Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2015-01-05       Impact factor: 5.594

5.  Benzodiazepines consumption: does dependence vary with age?

Authors:  Marie Gérardin; Caroline Victorri-Vigneau; Marylène Guerlais; Morgane Guillou-Landreat; Marie Grall-Bronnec; Pascale Jolliet
Journal:  Subst Use Misuse       Date:  2014-05-08       Impact factor: 2.164

Review 6.  Safety of benzodiazepines in the geriatric population.

Authors:  Subramoniam Madhusoodanan; Olivera J Bogunovic
Journal:  Expert Opin Drug Saf       Date:  2004-09       Impact factor: 4.250

Review 7.  Medications associated with falls in older people: systematic review of publications from a recent 5-year period.

Authors:  Hyerim Park; Hiroki Satoh; Akiko Miki; Hisashi Urushihara; Yasufumi Sawada
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

Review 8.  Benzodiazepine dependence: a shadowy diagnosis.

Authors:  P Tyrer
Journal:  Biochem Soc Symp       Date:  1993

9.  Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial.

Authors:  Cara Tannenbaum; Philippe Martin; Robyn Tamblyn; Andrea Benedetti; Sara Ahmed
Journal:  JAMA Intern Med       Date:  2014-06       Impact factor: 21.873

Review 10.  Withdrawing benzodiazepines in primary care.

Authors:  Malcolm Lader; Andre Tylee; John Donoghue
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more
  2 in total

Review 1.  [Dementia and comorbid conditions].

Authors:  W Hofmann
Journal:  Internist (Berl)       Date:  2017-02       Impact factor: 0.743

Review 2.  [Early onset substance abuse disorders and addictive diseases in old age].

Authors:  Dirk K Wolter
Journal:  Z Gerontol Geriatr       Date:  2018-09-04       Impact factor: 1.281

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.